Researchers from the Institute for Biomedical Research of Malaga and the Nanomedicine Platform (IBIMA Plataforma BIONAND) have developed a new methodology for early detection of breast cancer through one blood sample.
This new non-invasive method consists of DNA analysis massive sequencing, which allows to detect the presence of DNA secreted by tumor cells into the blood.
The project was led by researcher Iñaki Comino-Mendez and coordinated by Emilio Alba, Head of Intercenter Oncology Service at the Regional University Hospitals of Malaga and Virgen de la Victoria.
Iñaki Comino-Mendez explains that with this new technology, they have analyzed blood samplesbefore any medical intervention, 75 patients who presented mammograms with signs of breast cancer.
If abnormal images are found on mammograms, a biopsy is performed.
The results show that “the fact that there is a detectable tumor mutation in the blood means that this woman has an 86% chance of having a breast tumor,” according to Comino-Mendez.
Detection of breast cancer by a drop of blood provides more information than a biopsy
This type of diagnostic methodology has many advantages. For example, by providing more information about cancer than through biopsy common from one part of the tumor from Mom
The researcher emphasizes that “this is a very powerful tool for detecting tumors in asymptomatic people and the key to choosing the most appropriate therapy for each patient.”
In addition, he adds, “it will be very important for patients due to the ability early detection disease and its subsequent early treatment.
This new method, called liquid biopsy, is a less dangerous alternative to existing methods.
mammary cancer most frequent in women all over the world. Mammograms allow for early detection programs, and only if abnormal images are found, a breast biopsy is performed.
This new diagnostic method, called liquid biopsyrepresents an alternative to existing methods, with less risk and more effective for patients, emphasize the project leaders, who are members of the Cancer Network Biomedical Research Center (CIBERONC), owned by the Carlos III Health Institute (ISCIII).
Source: Hiper Textual
